20 articles
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
Maastricht University investigated whether NA, NAM, and tryptophan together could restore mitochondrial function in physically compromised older adults.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
84-person study reveals how targeted nutrition counseling impacts blood sugar, weight, and heart health in diabetic patients.
A completed University of Michigan trial explored how aerobic exercise training alters RAGE-mediated inflammatory pathways in type 2 diabetic adults.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
New research suggests extending overnight fasting from 10 to 16 hours may enhance muscle's ability to use dietary protein for growth.
New study tests whether meal timing combined with Mediterranean diet can reverse fatty liver disease better than diet alone.
176-person study explored personalized responses to refined carbs, whole grains, and intermittent fasting for optimal glucose control.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
UCSF study reveals how metformin and trimethoprim interfere with thiamine uptake, potentially affecting energy metabolism.
Major trial of 10,251 diabetics reveals surprising outcomes from aggressive blood sugar, blood pressure, and cholesterol management.
A completed Maastricht trial tests whether targeted protein and exercise can boost muscle protein synthesis before dialysis becomes necessary.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
German researchers test whether natural foods plus digital coaching can match diabetes remission rates of formula diets.
